title: Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer.
abstract: OBJECTIVE
  The aim of this prospective study was to assess the prognostic impact of serum tumor markers (Cyfra21-1, carcinoembryonic antigen, neuron-specific enolase, squamous cell carcinoma-antigen and TPAcyk) in patients with non-small cell lung cancer (NSCLC) receiving complete resection.
  
  
  METHODS
  Sixty-seven patients with histologically proven NSCLC and complete resection of stage I-IIIA disease were included. The serum levels of all markers were measured using commercially available immunoassays.
  
  
  RESULTS
  With a median follow-up of 86 months for surviving patients, those with initial Cyfra21-1 serum levels higher than 3.57 ng/ml had a significantly worse prognosis (P=0.014). The remaining serum tumor markers showed no prognostic impact. In a Cox regression model, Cyfra21-1 proved to be an independent prognostic factor for both overall survival and disease-free interval. In addition, Cyfra21-1 sustained as an independent prognostic factor in completely resected stage I/II disease.
  
  
  CONCLUSIONS
  With a cut-off value of 3.57 ng/ml, Cyfra 21-1 was an independent prognostic factor for survival in NSCLC-patients with complete resection. Further evaluation is needed, particularly in stage I/II disease. When the prognostic impact is confirmed with larger patient numbers this may contribute to the identification of stratification variables for future treatment approaches of NSCLC.
authors: Department of Medicine, Westfälische Wilhelms-Universität, 48129, Münster, Germany. reinmut@uni-muenster.de
authors: Niels
authors: N
authors: Reinmuth
authors: Burkhard
authors: B
authors: Brandt
authors: Michael
authors: M
authors: Semik
authors: Wolf-Peter
authors: WP
authors: Kunze
authors: Richard
authors: R
authors: Achatzy
authors: Hans H
authors: HH
authors: Scheld
authors: Petra
authors: P
authors: Broermann
authors: Wolfgang E
authors: WE
authors: Berdel
authors: Hans N
authors: HN
authors: Macha
authors: Michael
authors: M
authors: Thomas
mesh_terms: D000951:Antigens, Neoplasm / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology* / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053539:Keratin-19; D007633:Keratins; D008175:Lung Neoplasms / Q000473:pathology* / Q000601:surgery; D008297:Male; D010751:Phosphopyruvate Hydratase / Q000097:blood; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012044:Regression Analysis; D015843:Serpins; D016019:Survival Analysis; D019396:Tissue Polypeptide Antigen / Q000097:blood
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D053539:Keratin-19; D015843:Serpins; D019396:Tissue Polypeptide Antigen; C102012:antigen CYFRA21.1; C051072:squamous cell carcinoma-related antigen; D007633:Keratins; D010751:Phosphopyruvate Hydratase